Person

Ferrari, Nicolay

Dr. Nicolay Ferrari completed his graduate studies at the Université de Montréal in 1999. He then pursued his post-doctoral work at the Dana-Farber Cancer Institute of the Harvard Medical School (Boston MA) and at the National Cancer Institute of the National Institutes of Health (Bethesda MD) developing anti-angiogenic gene therapy approaches and the use of neuronal stem cells as delivery vehicles of therapeutic genes for the treatment of brain tumors. Dr. Ferrari recently completed a Graduate Diploma in Management and Business from McGill in 2012. Following his postdoctoral studies, he spent 12 years in the biotechnology sector, first at Celmed Biosciences as Group Leader and then at Topigen Pharmaceuticals. At Topigen, as Director Pharmacology, he provided leadership for discovery and preclinical research activities that lead to the development of three novel anti-inflammatory drug candidates for the treatment of respiratory diseases, one currently in Phase 2 for the treatment of asthma. Since 2011, Dr. Ferrari is a Lecturer at the Department of Pharmacology at the Université de Sherbrooke. Just prior to joining the Canadian Critical Care Trial Group, Dr. Ferrari was the Assistant Director of the Institute of Cancer Research of the Canadian Institutes of Health Research where he assisted the development of novel funding opportunities and public-private partnerships.